We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
-22.91%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$131M
AUM Growth
-$149M
Cap. Flow
-$94.6M
Cap. Flow %
-72.16%
Top 10 Hldgs %
79.41%
Holding
34
New
3
Increased
7
Reduced
6
Closed
13

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$7.68M
2
AMRN
Amarin Corp
AMRN
+$6.68M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$1.98M
4
KALV
KalVista Pharmaceuticals
KALV
+$888K
5
ACER
Acer Therapeutics Inc
ACER
+$777K

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$32.9M
2
ARWR icon
Arrowhead Research
ARWR
+$14.9M
3
CEMI
Chembio diagnostics, Inc.
CEMI
+$12.1M
4
VCYT icon
Veracyte
VCYT
+$7.69M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$7.07M

Sector Composition

Rank Sector Weight
1 Healthcare 82.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IOVA icon
1
Iovance Biotherapeutics
IOVA
$1.93B
$26.7M 20.38%
3,019,201
+796,500
+36% +$7.68M
ASMB icon
2
Assembly Biosciences
ASMB
$503M
$16.3M 12.4%
59,875
-17,625
-23% -$5.1M
KDMN
3
DELISTED
Kadmon Holdings, Inc.
KDMN
$15.7M 11.96%
7,538,000
+143,000
+2% +$360K
CASM
4
DELISTED
CAS Medical Systems, Inc.
CASM
$8.42M 6.42%
5,263,508
– –
XBI icon
5
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.62B
$7.17M 5.47%
100,000
– –
BHVN
6
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$6.93M 5.29%
187,500
+55,000
+42% +$1.98M
AMRN
7
Amarin Corp
AMRN
$297M
$5.95M 4.54%
21,875
+18,325
+516% +$6.68M
IMMU
8
DELISTED
Immunomedics Inc
IMMU
$5.71M 4.35%
400,000
-1,655,500
-81% -$32.9M
IMMU
9
PUT
DELISTED
Immunomedics Inc
IMMU
$5.71M 4.35%
+400,000
New +$7.94M
VCYT icon
10
Veracyte
VCYT
$3.58B
$5.57M 4.25%
442,500
-650,000
-59% -$7.69M
IRIX icon
11
IRIDEX
IRIX
$14.4M
$5.52M 4.21%
1,174,500
-773,000
-40% -$3.85M
ARGX icon
12
argenx
ARGX
$52B
$5.09M 3.88%
53,000
-52,000
-50% -$4.62M
KALV
13
DELISTED
KalVista Pharmaceuticals
KALV
$3.42M 2.61%
173,000
+44,156
+34% +$888K
XENE icon
14
Xenon Pharmaceuticals
XENE
$6.02B
$3.39M 2.59%
537,500
+55,000
+11% +$489K
ACER
15
DELISTED
Acer Therapeutics Inc
ACER
$2.88M 2.19%
143,000
+33,730
+31% +$777K
CEMI
16
DELISTED
Chembio diagnostics, Inc.
CEMI
$2.19M 1.67%
387,167
-1,643,366
-81% -$12.1M
BHVN
17
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.99M 1.52%
53,800
– –
VRAY
18
DELISTED
ViewRay, Inc.
VRAY
$1.89M 1.44%
311,500
– –
STRO icon
19
Sutro Biopharma
STRO
$416M
$410K 0.31%
+4,550
New +$549K
BCRX icon
20
BioCryst Pharmaceuticals
BCRX
$2.24B
$202K 0.15%
+25,000
New +$194K
OTLK icon
21
Outlook Therapeutics
OTLK
$171M
$15K 0.01%
182
– –
ARWR icon
22
CALL
Arrowhead Research
ARWR
$12.1B
– –
-200,000
Closed -$3.83M
ARWR icon
23
Arrowhead Research
ARWR
$12.1B
– –
-775,000
Closed -$14.9M
ASMB icon
24
CALL
Assembly Biosciences
ASMB
$503M
– –
-12,292
Closed -$5.48M
ASND icon
25
Ascendis Pharma A/S
ASND
$16B
– –
-71,500
Closed -$5.07M
1
2

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q4 2018 Portfolio in Review

As of Q4 2018, Acuta Capital Partners held 34 positions worth $131M, down 53% from $280M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Acuta Capital Partners withdrew a net $94.6M in Q4 2018, closing 13 positions and reducing 6 holdings. Its most notable exit was Arrowhead Research, an estimated $14.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 73% a quarter earlier.

Against the trend, Acuta Capital Partners opened a new position in Sutro Biopharma worth $410K.

  • Acuta Capital Partners's largest Q4 2018 buy was Sutro Biopharma: 4,550 shares worth $410K.
  • Acuta Capital Partners added most to Iovance Biotherapeutics in Q4 2018, an estimated $7.68M increase.
  • Acuta Capital Partners's biggest Q4 2018 reduction was Immunomedics Inc, cutting an estimated $32.9M.
  • Acuta Capital Partners fully exited Arrowhead Research in Q4 2018, selling an estimated $14.9M.
  • Acuta Capital Partners's ten largest holdings make up 79% of its $131M portfolio in Q4 2018.
  • Acuta Capital Partners opened 3 new positions and closed 13 in Q4 2018.
  • Acuta Capital Partners's portfolio value fell 53% quarter-over-quarter to $131M.

Based on Acuta Capital Partners's 13F filing for Q4 2018, filed 14 Feb 2019.